Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NC318 |
Synonyms | |
Therapy Description |
NC318 is a monoclonal antibody that binds to sialic acid binding Ig-like lectin 15 (Siglec-15) expressed on tumor-associated macrophages, which may disrupt T-cell response inhibition, leading to antitumor activity (PMID: 31806628). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NC318 | NC-318|NC 318|Anti-S15 mAb NC318 | NC318 is a monoclonal antibody that binds to sialic acid binding Ig-like lectin 15 (Siglec-15) expressed on tumor-associated macrophages, which may disrupt T-cell response inhibition, leading to antitumor activity (PMID: 31806628). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04699123 | Phase II | NC318 + Pembrolizumab NC318 | The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT03665285 | Phase Ib/II | NC318 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |